Advertisement
J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1194/jlr.M400009-JLR200 on May 16, 2004

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M400009-JLR200v1
45/8/1475    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goudriaan, J. R.
Right arrow Articles by Rensen, P. C. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goudriaan, J. R.
Right arrow Articles by Rensen, P. C. N.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 45, 1475-1481, August 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology

The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis

Jeltje R. Goudriaan*, Sonia M. S. Espirito Santo*, Peter J. Voshol1,*,{dagger}, Bas Teusink*, Ko Willems van Dijk§,**, Bart J. M. van Vlijmen*, Johannes A. Romijn{dagger}, Louis M. Havekes*,§ and Patrick C. N. Rensen*,§

* Institute for Applied Scientific Research Prevention and Health, Gaubius Laboratory, 2301 CE Leiden, The Netherlands
{dagger} Department of Endocrinology and Diabetes, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
§ Department of Cardiology and General Internal Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
** Molecular Genetics and Cell Biology-Department of Human Genetics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands

Published, JLR Papers in Press, May 16, 2004. DOI 10.1194/jlr.M400009-JLR200

1 To whom correspondence should be addressed. e-mail: pj.voshol{at}pg.tno.nl


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The VLDL receptor (VLDLr) is involved in tissue delivery of VLDL-triglyceride (TG)-derived FFA by facilitating the expression of lipoprotein lipase (LPL). However, vldlr–/– mice do not show altered plasma lipoprotein levels, despite reduced LPL expression. Because LPL activity is crucial in postprandial lipid metabolism, we investigated whether the VLDLr plays a role in chylomicron clearance. Fed plasma TG levels of vldlr–/– mice were 2.5-fold increased compared with those of vldlr+/+ littermates (1.20 ± 0.37 mM vs. 0.47 ± 0.18 mM; P < 0.001). Strikingly, an intragastric fat load led to a 9-fold increased postprandial TG response in vldlr–/– compared with vldlr+/+ mice (226 ± 188 mM/h vs. 25 ± 11 mM/h; P < 0.05). Accordingly, the plasma clearance of [3H]TG-labeled protein-free chylomicron-mimicking emulsion particles was delayed in vldlr–/– compared with vldlr+/+ mice (half-life of 12.0 ± 2.6 min vs. 5.5 ± 0.9 min; P < 0.05), with a 60% decreased uptake of label into adipose tissue (P < 0.05). VLDLr deficiency did not affect the plasma half-life and adipose tissue uptake of albumin-complexed [14C]FFA, indicating that the VLDLr facilitates postprandial LPL-mediated TG hydrolysis rather than mediating FFA uptake.

We conclude that the VLDLr plays a major role in the metabolism of postprandial lipoproteins by enhancing LPL-mediated TG hydrolysis.

Abbreviations: apoE, apolipoprotein E; HL, hepatic lipase; LDLr, LDL receptor; LPL, lipoprotein lipase; TG, triglyceride; VLDLr, VLDL receptor

Supplementary key words adipose tissue • free fatty acids • lipoprotein lipase • postprandial lipid metabolism • very low density lipoprotein-like emulsion • transgenic mice


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The VLDL receptor (VLDLr) is a member of the LDL receptor (LDLr) family (1). The most striking features that distinguish the VLDLr from the LDLr are its ligand-binding properties and its tissue distribution (1, 2). The VLDLr is, like lipoprotein lipase (LPL), uniquely expressed at sites that are involved in the peripheral metabolism of triglyceride (TG)-rich lipoproteins. The VLDLr is highly expressed on the capillary endothelium (3) of skeletal muscle, heart, and adipose tissue and only in trace amounts in the liver, whereas the LDLr is abundantly expressed in the liver (1, 2). Initial in vitro studies have demonstrated that the VLDLr is a receptor for several apolipoprotein E (apoE)-containing lipoprotein ligands, such as VLDL, intermediate density lipoproteins, and chylomicrons (2, 4). The binding of these lipoprotein particles to the VLDLr is stimulated by apoE and LPL (4, 5) and inhibited by the 39 kDa receptor-associated protein (6). Based on these studies, it has initially been suggested that the VLDLr could play a role in the peripheral binding and subsequent internalization of TG-rich lipoproteins (4, 5). More recently, Obunike et al. (7) showed in vitro that the VLDLr is involved in the transcytosis of active LPL across endothelial cells. Therefore, it is now believed that the VLDLr may possibly function mainly by facilitating the binding of TG-rich lipoproteins in the capillary bed in concert with LPL, leading to the subsequent delivery of TG-derived FFAs to the underlying tissues active in FFA metabolism (5, 8).

To establish whether the VLDLr plays a role in lipid metabolism in vivo, Frykman et al. (9) generated mice lacking the VLDLr by gene targeting. Although the initial in vitro data suggested that the VLDLr may play a prominent role in TG metabolism (4, 5), these vldlr–/– mice exhibited no differences in plasma lipoproteins on a normal chow diet (9). However, stressing the FA metabolism by prolonged fasting (10), a high-fat diet (10), or cross-breeding on a hyperlipidemic ob/ob (10) or ldlr–/– (11) background, VLDLr deficiency led to a hypertriglyceridemic phenotype in mice. In addition, under conditions of dietary stress, we showed that despite the development of hypertriglyceridemia, vldlr–/– mice were protected from diet-induced obesity (10). Recently, Yagyu et al. (12) showed that the VLDLr can play a role in the delivery of VLDL-TG-derived FFAs to adipose tissue, because VLDLr deficiency resulted in defective VLDL catabolism in vivo associated with reduced activity of LPL, albeit under prolonged fasting conditions. Compared with the fasting state, LPL activity in adipose tissue is increased postprandially (13), and the flux of TG-derived FFA to adipose tissue is greatly enhanced during the postprandial state (14). Therefore, we hypothesize that the VLDLr plays a crucial role in postprandial lipoprotein metabolism.

Thus, the aim of the present study was to evaluate the role of the VLDLr in chylomicron metabolism. We show that VLDLr deficiency in mice severely impairs chylomicron catabolism. Furthermore, postprandial TG-derived FFA uptake in adipose tissue is severely impaired, indicating that the VLDLr is required for optimal LPL-mediated chylomicron processing in vivo. These findings can fully explain our earlier observation that vldlr–/– mice are protected against diet-induced and genetically induced obesity (10). From the present study, we conclude that the VLDLr plays a major role in postprandial lipoprotein metabolism by facilitating LPL-mediated TG hydrolysis.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Animals
Vldlr–/– mice originated from the Jackson Laboratories and were bred in our animal facility in Leiden. Nontransgenic littermates (vldlr+/+) were used as controls. All mice used in this study were housed under standard conditions with free access to water and food and a normal 12 h light/dark cycle (lights on at 7:00 AM and off at 7:00 PM). Principles of laboratory animal care were followed, and the animal ethics committee of our institute approved all animal experiments.

Plasma lipid analysis
To determine postprandial and fasting lipid levels, tail vein blood was collected from male vldlr–/– and vldlr+/+ mice at 7:00 AM just after the end of the dark cycle (fed state) and at 11:00 AM (after a 4 h fasting period) into chilled paraoxon-coated capillary tubes to prevent ongoing lipolysis (15). These tubes were placed on ice and immediately centrifuged at 4°C. Plasma levels of total cholesterol, TG (corrected for free glycerol), and FFA were determined enzymatically using commercially available kits and standards (236691, Boehringer, Mannheim, Germany; 337-B GPO-Trinder kit, Sigma, St. Louis, MO; Nefa-C kit, Wako Chemicals GmbH, Neuss, Germany).

LPL and hepatic lipase enzyme activity
Female vldlr–/– and vldlr+/+ mice were fasted for 4 h, and postheparin plasma was obtained 10 min after a tail vein injection of heparin (0.1 U/g body weight) (Leo Pharma BV, Weesp, The Netherlands). The LPL activity was determined in postheparin plasma as described (16).

Intragastric fat load
To investigate the handling of postprandial TG, vldlr–/– and vldlr+/+ mice were given an intragastric 200 µl olive oil bolus after an overnight fast. Blood samples were drawn at the indicated time points after administration. TG concentrations were determined in plasma as described above and are presented as relative increase from time 0.

Preparation of emulsion particles
Protein-free chylomicron-mimicking TG-rich emulsion particles were prepared essentially as described by Rensen et al. (17) from 100 mg of total lipid at a weight ratio of triolein (Sigma)-egg yolk phosphatidylcholine (Lipoid, Ludwigshafen, Germany)-lysophosphatidylcholine (Sigma)-cholesteryl oleate (Sigma)-cholesterol (Sigma) of 70:22.7:2.3:3.0:2.0 in the presence of 200 µCi of glycerol tri[9,10(n)-3H]oleate ([3H]TG) (Amersham, Little Chalfont, UK). Lipids were hydrated in 10 ml of 2.4 M NaCl, 10 mM HEPES, and 1 mM EDTA, pH 7.4, and sonicated for 30 min at 10 µm output using a Soniprep 150 (MSE Scientific Instruments) equipped with a water bath for temperature (54°C) maintenance. Subsequently, the emulsion was separated into fractions with different average sizes by density gradient ultracentrifugation (17).

In vivo lipolysis: bolus experiment
Fed female vldlr –/– and vldlr +/+ mice were anesthetized (0.5 mg/kg Domitor, Pfizer Animal Health, Capelle a/d IJssel, The Netherlands; 0.05 mg/kg Fentanyl Bipharma, Pharma Hameln, Hameln, Germany; and 5 mg/kg midazolam, Roche, Mijdrecht, The Netherlands), and the abdomens were opened. [3H]TG-labeled emulsion particles were injected via the vena cava inferior at t = 0 as a large bolus (1.0 mg of TG), resulting in plasma TG levels well above the endogenous TG concentration. At the time points indicated after injection, small blood samples (30 µl) were taken from the vena cava inferior and serum 3H-radioactivity was measured. At 15 min, the mice were sacrificed, and their organs excised and weighed. Radioactivity was counted after the tissues were dissolved in Solvable (Packard Bioscience, Groningen, The Netherlands), and corrections were made for the serum radioactivity in the tissues as described by Rensen et al. (17).

In vivo lipolysis: infusion experiment
After 2 weeks on a high-fat diet (46.2% of the calories as fat; Hope Farms, Woerden, The Netherlands), fed male vldlr–/– and vldlr+/+ mice were anesthetized and an infusion needle, connected to a Harvard microdialysis low-flow 11 minipump (Holliston, MA), was inserted into the tail vein. [3H]TG-labeled emulsion particles (1.0 mg TG/ml) and a trace amount of [14C]palmitic acid (Amersham) complexed to BSA (2%) in the presence of citrate (3 µg/ml) were infused at a rate of 0.2 ml/h for 2 h to achieve steady-state TG levels. After 1.5 and 2 h, a 150 µl blood sample was taken by tail bleeding. Subsequently, the mice were killed and their organs quickly removed and frozen in liquid nitrogen. Plasma levels of TG and FFA were determined as described above. Lipids were extracted from plasma according to Bligh and Dyer (18). The lipid fraction was dried under nitrogen, dissolved into chloroform-methanol (5:1, v/v), and subjected to TLC (LK5D gel 150; Whatman) using hexane-diethylether-acetic acid (83:16:1, v/v/v) as mobile phase. Lipid spots were visualized by I2 vapor and scraped off, lipids were dissolved in hexane, and radioactivity was measured. Tissues were dissolved in 3 M KOH in 50% (v/v) ethanol at 70°C for 1 h. Retention of radioactivity in the tissues was measured per milligram of protein and corrected for the corresponding plasma-specific activities of [3H]TG and [14C]FFA.

Statistical analysis
The Mann-Whitney nonparametric test for two independent samples was used to define differences between vldlr–/– and vldlr+/+ mice. The criterion for significance was set at P < 0.05. All data are presented as means ± SD.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
VLDLr deficiency increases fed TG levels
To investigate the effect of VLDLr deficiency on postprandial lipid metabolism, plasma lipid levels were measured in fed and 4 h fasting male vldlr–/– and vldlr+/+ mice (Table 1). Whereas no significant differences were found between these mice with respect to TG, FFA, and cholesterol levels after a 4 h fast, fed vldlr–/– mice did show significantly increased levels of TG (2.5-fold) and FFA (1.6-fold), but not cholesterol, compared with vldlr+/+ mice. In fact, postprandial chylomicron-TG levels (i.e., the difference between fed and fasting TG levels) were even 4-fold increased upon VLDLr deficiency. The plasma lipid levels in female mice did not differ significantly from those in male mice, and fed TG levels were also consistently higher in female vldlr–/– mice (data not shown). These data suggest that both male and female vldlr–/– mice have reduced postprandial TG clearance under normal feeding conditions.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Effect of VLDLr deficiency on fed and 4 h fasting plasma lipid levels

 
VLDLr deficiency decreases LPL activity
Because vldlr–/– mice showed no differences compared with vldlr+/+ mice with respect to intestinal lipid absorption and hepatic VLDL production (10), the postprandial hypertriglyceridemia can be explained by the impaired lipolytic processing of chylomicrons. To confirm a decreased plasma lipolytic activity in vldlr–/– mice as shown by Yagyu et al. (12), hepatic lipase (HL) and LPL activities were measured in postheparin plasma. As shown in Fig. 1, the activity of LPL was significantly decreased (20%; P < 0.05) in vldlr–/– compared with wild-type mice, whereas no differences were observed with respect to HL activity.



View larger version (14K):
[in this window]
[in a new window]
  		Fig. 1. Effect of VLDL receptor (VLDLr) deficiency on plasma lipoprotein lipase (LPL) and hepatic lipase (HL) activity. Postheparin plasma was obtained from vldlr+/+ (closed bars) and vldlr–/– (open bars) mice, and triglyceride (TG) hydrolase activity was measured in the absence (i.e., LPL and HL) or presence (i.e., HL) of 1 M NaCl. Values represent means ± SD of 10 vldlr+/+ and 8 vldlr–/– mice. * P < 0.05.

 
VLDLr deficiency increases postprandial TG response
To investigate further the role of the VLDLr in postprandial lipoprotein metabolism, we administered an intragastric olive oil load by gavage to male vldlr–/– and vldlr+/+ mice (Fig. 2). Strikingly, whereas wild-type mice showed only a mild increase in TG levels at 2 h after administration (from 0.3 ± 0.1 to 1.0 ± 0.4 mM), which reached baseline levels again by 8 h, vldlr–/– mice showed a severely increased and prolonged hypertriglyceridemia. The increase in TG was already 7-fold compared with the level in wild-type mice at 2 h and reached a maximum only at 8 h after the fat load. Therefore, the postprandial TG response in vldlr–/– compared with vldlr+/+ mice was 9-fold increased (AUC: 226 ± 188 mM/h vs. 25 ± 11 mM/h), demonstrating that VLDLr deficiency leads to severe impairment of postprandial TG clearance. Again, similar findings were observed for female mice.



View larger version (14K):
[in this window]
[in a new window]
  		Fig. 2. Effect of VLDLr deficiency on postprandial TG response. Overnight-fasted male vldlr+/+ (closed circles) and vldlr–/– (open circles) mice were given an intragastric 200 µl olive oil bolus. Blood samples were drawn at 0, 2, 4, 8, and 24 h after the bolus. TG concentrations were determined in plasma and corrected for TG values at time 0. Values represent means ± SD of seven vldlr+/+ and eight vldlr–/– mice. * P < 0.05.

 
VLDLr deficiency decreases uptake of emulsion TG-derived FFA by adipose tissue
Subsequently, we investigated whether VLDLr deficiency affects the delivery of postprandial lipoprotein-derived FFA to tissues with the highest LPL expression in the fed state [i.e., adipose tissue and heart (19)]. To exclude interindividual variations with respect to intestinal lipid absorption, [3H]TG-labeled emulsion particles that closely mimic chylomicrons were injected intravenously as a bolus into mice of both genotypes (Fig. 3). Whereas an efficient monoexponential TG clearance was observed in wild-type mice with a serum half-life of 5.5 ± 0.9 min, vldlr–/– mice showed a delayed plasma TG clearance, as indicated by the 2.2-fold increased serum half-life (Fig. 3A, Table 2), confirming a disturbance in postprandial particle clearance. The delayed TG clearance in vldlr–/– mice was accompanied by a 60% decreased uptake of 3H activity by adipose tissue and a 55% decreased uptake by skeletal muscle per mass unit (Fig. 3B). As depicted in Fig. 3B, the uptake of [3H]TG-derived radiolabel by the heart per mass unit was higher in vldlr–/– mice. However, it was noted that the total heart weight of vldlr–/– mice was 25% reduced compared with that of wild-type mice (0.74 ± 0.06 g vs. 0.98 ± 0.09 g; P < 0.05). Therefore, the total uptake of 3H radioactivity by the heart was not different (P = 0.149) when corrected for total heart weight.



View larger version (22K):
[in this window]
[in a new window]
  		Fig. 3. Effect of VLDLr deficiency on the serum decay and tissue distribution of [3H]TG-labeled emulsion particles. [3H]TG-labeled chylomicron-like emulsion particles were injected intravenously into fed anesthetized vldlr+/+ (closed symbols) and vldlr–/– (open symbols) mice. At the time points indicated, the serum decay was determined. A: The serum values obtained at 1 min after infection were set at 100%. B: At 15 min after injection, the uptake of [3H]TG-derived radioactivity by adipose tissue, skeletal muscle, and heart was determined. Values represent means ± SD of four mice per group. * P < 0.05.

 

View this table:
[in this window]
[in a new window]
  		TABLE 2. Effect of VLDLr deficiency on the plasma half-life of [3H]TG and [14C]FFA after bolus injection and continuous infusion

 


View larger version (21K):
[in this window]
[in a new window]
  		Fig. 4. Effect of VLDLr deficiency on the uptake of TG-derived and albumin-derived FFA by adipose tissue and heart. Fed vldlr+/+ (closed bars) and vldlr–/– (open bars) mice were infused for 2 h with [3H]TG-labeled chylomicron-like emulsion particles and albumin-bound [14C]FFA. After 2 h, the mice were killed and the retention of [3H]TG and [14C]FFA was determined in adipose tissue (A) and heart (B) and corrected for the specific activities of both radiolabels in plasma. Values represent means ± SD of seven vldlr+/+ and four vldlr–/– mice. * P < 0.05.

 
VLDLr deficiency does not affect the uptake of albumin-bound FFAs by adipose tissue
To evaluate whether the VLDLr may function by transporting FFAs across the endothelial layer per se rather than by facilitating LPL-mediated lipolysis, [3H]TG-labeled chylomicron-like emulsion particles were continuously infused together with albumin-bound [14C]palmitate on a high-fat diet. On this diet, similar increasing effects of VLDLr deficiency on fed plasma TG levels were observed compared with the chow diet (1.10 ± 0.27 mM vs. 0.68 ± 0.15 mM for vldlr–/– mice and wild-type littermates, respectively; P < 0.05). Plasma half-lives of both [3H]TG and [14C]FFA were calculated from steady-state kinetics (14). Whereas the plasma clearance of [3H]TG under these conditions was again delayed in vldlr–/– compared with vldlr+/+ mice, the plasma half-life of [14C]FFA was not affected significantly (Table 2). Accordingly, the uptake of [3H]TG-derived activity by adipose tissue per mass unit was 60% decreased in vldlr–/– mice (Fig. 4A). The uptake of [3H]TG-derived activity by the heart per mass unit was increased in vldlr–/– mice (Fig. 4B), but total uptake by the heart was unaffected. The uptake by skeletal tissue was also not affected (data not shown). No differences were found with respect to [14C]FFA uptake by adipose tissue, skeletal muscle, or heart (Fig. 4B). These data demonstrate that the VLDLr does not seem to be involved in the transport and storage of albumin-bound FFAs to the underlying adipose tissue per se but rather enhances LPL-mediated TG hydrolysis.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Although earlier studies have reported that the VLDLr is able to bind and internalize TG-rich lipoproteins as mediated via apoE and/or LPL in vitro (4, 5), vldlr–/– mice were initially reported to have no phenotype with respect to lipid and/or lipoprotein levels (9). Placing FFA metabolism under stress by feeding vldlr–/– mice a high-fat diet or cross-breeding these mice onto a hyperlipidemic background (10, 11) or by prolonged fasting (10, 12) did lead to a hypertriglyceridemic phenotype, which was not caused by increased hepatic VLDL production (10). A recent study has shown that a decreased VLDL catabolism in vldlr–/– compared with vldlr+/+ mice was related to decreased LPL activity (12). These data were derived from mice that underwent a prolonged 16 h fasting period (12). However, because LPL is more crucial in postprandial lipoprotein metabolism, we hypothesized that the role of the VLDLr may be most prominent under postprandial conditions, during which the flux of TG-derived FFAs to adipose tissue is greatly enhanced (14). Therefore, we performed as yet unaddressed studies to evaluate a function of the VLDLr in chylomicron catabolism using vldlr–/– mice and wild-type littermates. Indeed, we found that the VLDLr has a prominent physiological function in the lipolysis of postprandial lipoproteins, with a subsequent decreased delivery of particle TG-derived FAs to adipose tissue, and not in the uptake of FAs per se.

After a 4 h fast, which allows the complete clearance of plasma chylomicrons, plasma lipid levels in vldlr–/– and vldlr+/+ mice were not different, which is in agreement with reports by others (9). However, analysis of the plasma of mice just after the end of the dark cycle, which most closely resembles a normal fed condition, showed a 2.5-fold increase in TG levels in vldlr–/– mice along with a 1.6-fold increase in FFA levels. Taking account of the fact that postprandial TG levels include both VLDL-TG and chylomicron-TG, it could be calculated that postprandial chylomicron levels differed to an even larger extent (i.e., 4-fold). By forcing rapid and extensive intestinal chylomicron production by the intragastric administration of a large olive oil load, vldlr–/– mice showed a 9-fold increased TG response. Because we had previously excluded the possibility of decreased intestinal lipid absorption and hepatic VLDL production in vldlr–/– mice (10), these data confirm the hypothesis that VLDLr-deficient mice are unable to efficiently clear postprandial TG from the plasma. LPL is a major player in peripheral TG hydrolysis, and the LPL activity appeared to be 20% decreased (P < 0.05) in female vldlr–/– mice, which is in agreement with recent observations in male vldlr–/– mice by others (12). The decreased postheparin LPL activity is not solely attributable to decreased adipose tissue stores, because Yagyu et al. (12) showed that VLDLr deficiency also reduces the specific LPL activity in adipose tissue per mass unit.

The involvement of a reduced peripheral lipolysis of postprandial lipoproteins as part of the mechanism underlying the disturbed postprandial TG clearance was established by performing kinetic studies with [3H]TG-labeled chylomicron-mimicking emulsion particles. These emulsions have previously been shown to be true chylomicron mimics with respect to rapid apolipoprotein acquisition from plasma, LPL-mediated remnant formation, and efficient apoE-mediated hepatic uptake of core remnants by the LDLr and LDLr-related protein (17). Both upon intravenous bolus injection and continuous infusion, the plasma half-life of TG was prolonged in vldlr–/– compared with vldlr+/+ mice in the fed state. Accordingly, the distribution of [3H]TG-derived FFAs into adipose tissue was 60% decreased, irrespective of the mode of administration, bolus or continuous infusion. Taking into account that the total fat pad mass is reduced in vldlr–/– mice compared with wild-type littermates (9, 10), the difference in total uptake of radiolabel by adipose tissue is even more pronounced. Our findings complement the data of Yagyu et al. (12), who showed decreased VLDL-TG catabolism in vldlr–/– mice that had fasted for 16 h. However, they observed no change in the uptake of VLDL-TG by adipose tissue and a reduced uptake by heart and muscle in VLDLr deficiency, whereas we find a significantly decreased uptake of chylomicron-like emulsion TG by adipose tissue with no consistent reduction in uptake of TG by heart or muscle. Although substrate variation (i.e., emulsion particles vs. native VLDL) may have contributed to the observed discrepancy, the differences between the two studies can be fully explained by the natural regulation of tissue LPL levels by the feeding state, as prolonged fasting induces a gradually decreased expression of LPL by adipose tissue whereas that of heart and muscle is gradually increased (13, 19–23). Furthermore, under fed conditions, the flux of TG-derived FFAs to adipose tissue is greatly enhanced compared with the fasting state (14). The finding that the VLDLr is crucially involved in the uptake of chylomicron-TG-derived FFA by adipose tissue appears to fully explain the prevention of high-fat-diet-induced obesity in vldlr–/– mice as we described previously (10). Clearance of albumin-bound FFAs from the circulation did not seem to be affected by VLDLr deficiency, because the plasma half-life of albumin-bound FFAs was not significantly different between fed vldlr–/– mice and their littermate controls. However, a tendency toward a 25% increased half-life of FFAs in fed vldlr–/– mice was observed (Table 2), which is in agreement with the reduced FFA turnover we previously reported for fasted vldlr–/– mice (10). Taken together with the observation that plasma FFA levels were also significantly increased in fed mice (Table 1), we cannot exclude that the VLDLr may have an additional function in FFA turnover per se.

The effect of reduced peripheral lipolysis in VLDLr deficiency is thus likely to be one of the reasons underlying the postprandial hypertriglyceridemia, confirming previous reports on the crucial involvement of LPL in TG metabolism. First, LPL knockout mice do not survive, most probably because of extreme hypertriglyceridemia (24). Conversely, mice that overexpress LPL show a decreased postprandial TG response (25). Similarly, transgenic mice overexpressing the main endogenous LPL inhibitor apoC-III develop hypertriglyceridemia (26), whereas apoc3–/– mice exhibit reduced plasma TG levels and are protected from postprandial hypertriglyceridemia (26, 27).

Mice heterozygous for a mutation in the LPL gene (lpl +/–) were shown to have a 43% decreased postheparin LPL activity (28). In these mice, plasma TG levels were increased during ad libitum feeding and after fasting for 12 h (28). In addition, the response to orally administered vitamin A-containing corn oil was impaired in lpl +/– mice compared with wild-type littermates, as shown by a 3-fold increased vitamin A response (24). Although comparison of vldlr–/– mice with lpl +/– mice reveals similarities with respect to its impeding effects on TG metabolism, the effects of VLDLr deficiency on chylomicron catabolism are much more severe and cannot be explained solely by a modest 20% reduced LPL expression. Despite less affected LPL levels, the increasing effects of VLDLr deficiency on the postprandial TG response is much more dramatic (i.e., 9-fold) than the effects of LPL heterozygosity (i.e., 5-fold) (our unpublished observations). These data indicate that besides affecting LPL expression by its chaperone function (7) or LPL binding properties (4), the VLDLr is likely to participate in chylomicron catabolism by bridging of particles to the endothelial surface ("docking function"), thereby facilitating the LPL-particle interaction. In addition, the involvement of the VLDLr in lipoprotein internalization, as has been shown by VLDLr-expressing cells in vitro (4, 5) and by hepatocytes after recombinant adenovirus-mediated transfer of the VLDLr in vivo (29), cannot be conclusively eliminated as an additional factor contributing to TG clearance.

To summarize, we have shown that VLDLr deficiency leads to a disturbed clearance of postprandial lipoproteins into peripheral tissues such as adipose tissue, which can explain our previous findings that vldlr–/– mice are protected from diet-induced obesity. We conclude that the VLDLr plays a major physiological role in postprandial lipoprotein metabolism by enhancing LPL-mediated TG hydrolysis, with the subsequent delivery of FFAs to adipose tissue.


   ACKNOWLEDGMENTS
 
The authors are grateful to Marijke Voskuilen for excellent technical assistance. The research described in this paper is supported by the Leiden University Medical Center (Gisela Thier Fellowship to P.C.N.R.), the Netherlands Organization for Scientific Research [Netherlands Scientific Research Council (NWO) Grant 903-39-192/194, NWO VIDI Grant 917.36.351, and NWO VENI Grant 916.36.071], and the Netherlands Diabetes Foundation (Dutch Diabetes Research Foundation Grant 96.604).

Submitted on January 13, 2004
Revised on May 3, 2004


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
  1. Sakai, J., A. Hoshino, S. Takahashi, Y. Miura, H. Ishii, H. Suzuki, Y. Kawarabayasi, and T. Yamamoto. 1994. Structure, chromosome location, and expression of the human very low density lipoprotein receptor gene. J. Biol. Chem. 269: 2173–2182.[Abstract/Free Full Text]

  2. Takahashi, S., Y. Kawarabayasi, T. Nakai, J. Sakai, and T. Yamamoto. 1992. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc. Natl. Acad. Sci. USA. 89: 9252–9256.[Abstract/Free Full Text]

  3. Wyne, K. L., K. Pathak, M. C. Seabra, and H. H. Hobbs. 1996. Expression of the VLDL receptor in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 16: 407–415.[Abstract/Free Full Text]

  4. Niemeier, A., M. Gafvels, J. Heeren, N. Meyer, B. Angelin, and U. Beisiegel. 1996. VLDL receptor mediates the uptake of human chylomicron remnants in vitro. J. Lipid Res. 37: 1733–1742.[Abstract]

  5. Takahashi, S., J. Suzuki, M. Kohno, K. Oida, T. Tamai, S. Miyabo, T. Yamamoto, and T. Nakai. 1995. Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J. Biol. Chem. 270: 15747–15754.[Abstract/Free Full Text]

  6. Battey, F. D., M. E. Gafvels, D. J. FitzGerald, W. S. Argraves, D. A. Chappell, J. F. Strauss, and D. K. Strickland. 1994. The 39-kDa receptor-associated protein regulates ligand binding by the very low density lipoprotein receptor. J. Biol. Chem. 269: 23268–23273.[Abstract/Free Full Text]

  7. Obunike, J. C., E. P. Lutz, Z. Li, L. Paka, T. Katopodis, D. K. Strickland, K. F. Kozarsky, S. Pillarisetti, and I. J. Goldberg. 2001. Transcytosis of lipoprotein lipase across cultured endothelial cells requires both heparan sulfate proteoglycans and the very low density lipoprotein receptor. J. Biol. Chem. 276: 8934–8941.[Abstract/Free Full Text]

  8. Beisiegel, U., and J. Heeren. 1997. Lipoprotein lipase (EC 3.1.1.34) targeting of lipoproteins to receptors. Proc. Nutr. Soc. 56: 731–737.[CrossRef][Medline]

  9. Frykman, P. K., M. S. Brown, T. Yamamoto, J. L. Goldstein, and J. Herz. 1995. Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA. 92: 8453–8457.[Abstract/Free Full Text]

  10. Goudriaan, J. R., P. J. Tacken, V. E. Dahlmans, M. J. Gijbels, K. W. van Dijk, L. M. Havekes, and M. C. Jong. 2001. Protection from obesity in mice lacking the VLDL receptor. Arterioscler. Thromb. Vasc. Biol. 21: 1488–1493.[Abstract/Free Full Text]

  11. Tacken, P. J., B. Teusink, M. C. Jong, D. Harats, L. M. Havekes, K. W. van Dijk, and M. H. Hofker. 2000. LDL receptor deficiency unmasks altered VLDL triglyceride metabolism in VLDL receptor transgenic and knockout mice. J. Lipid Res. 41: 2055–2062.[Abstract/Free Full Text]

  12. Yagyu, H., E. P. Lutz, Y. Kako, S. Marks, Y. Hu, S. Y. Choi, A. Bensadoun, and I. J. Goldberg. 2002. Very low density lipoprotein (VLDL) receptor-deficient mice have reduced lipoprotein lipase activity. Possible causes of hypertriglyceridemia and reduced body mass with VLDL receptor deficiency. J. Biol. Chem. 277: 10037–10043.[Abstract/Free Full Text]

  13. Zechner, R. 1997. The tissue-specific expression of lipoprotein lipase: implications for energy and lipoprotein metabolism. Curr. Opin. Lipidol. 8: 77–88.[CrossRef][Medline]

  14. Teusink, B., P. J. Voshol, V. E. Dahlmans, P. C. Rensen, H. Pijl, J. A. Romijn, and L. M. Havekes. 2003. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes. 52: 614–620.[Abstract/Free Full Text]

  15. Zambon, A., S. I. Hashimoto, and J. D. Brunzell. 1993. Analysis of techniques to obtain plasma for measurement of levels of free fatty acids. J. Lipid Res. 34: 1021–1028.[Abstract]

  16. Zechner, R. 1990. Rapid and simple isolation procedure for lipoprotein lipase from human milk. Biochim. Biophys. Acta. 1044: 20–25.[Medline]

  17. Rensen, P. C., N. Herijgers, M. H. Netscher, S. C. Meskers, M. van Eck, and T. J. van Berkel. 1997. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J. Lipid Res. 38: 1070–1084.[Abstract]

  18. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Med. Sci. 37: 911–917.

  19. Enerback, S., and J. M. Gimble. 1993. Lipoprotein lipase gene expression: physiological regulators at the transcriptional and post-transcriptional level. Biochim. Biophys. Acta. 1169: 107–125.[Medline]

  20. Goldberg, I. J., and M. Merkel. 2001. Lipoprotein lipase: physiology, biochemistry, and molecular biology. Front. Biosci. 6: D388–D405.[Medline]

  21. Kwok, S., A. Singh-Bist, V. Natu, and F. B. Kraemer. 1997. Dietary regulation of the very low density lipoprotein receptor in mouse heart and fat. Horm. Metab. Res. 29: 524–529.[Medline]

  22. Olivecrona, T., M. Bergo, M. Hultin, and G. Olivecrona. 1995. Nutritional regulation of lipoprotein lipase. Can. J. Cardiol. 11 (Suppl. G): 73G–78G.

  23. Zechner, R., J. Strauss, S. Frank, E. Wagner, W. Hofmann, D. Kratky, M. Hiden, and S. Levak-Frank. 2000. The role of lipoprotein lipase in adipose tissue development and metabolism. Int. J. Obes. Relat. Metab. Disord. 24 (Suppl. 4): 53–56.

  24. Weinstock, P. H., C. L. Bisgaier, K. Aalto-Setala, H. Radner, R. Ramakrishnan, S. Levak-Frank, A. D. Essenburg, R. Zechner, and J. L. Breslow. 1995. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J. Clin. Invest. 96: 2555–2568.

  25. Shimada, M., H. Shimano, T. Gotoda, K. Yamamoto, M. Kawamura, T. Inaba, Y. Yazaki, and N. Yamada. 1993. Overexpression of human lipoprotein lipase in transgenic mice. Resistance to diet-induced hypertriglyceridemia and hypercholesterolemia. J. Biol. Chem. 268: 17924–17929.[Abstract/Free Full Text]

  26. Ito, Y., N. Azrolan, A. O'Connell, A. Walsh, and J. L. Breslow. 1990. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 249: 790–793.[Abstract/Free Full Text]

  27. Jong, M. C., P. C. Rensen, V. E. Dahlmans, H. van der Boom, T. J. van Berkel, and L. M. Havekes. 2001. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J. Lipid Res. 42: 1578–1585.[Abstract/Free Full Text]

  28. Coleman, T., R. L. Seip, J. M. Gimble, D. Lee, N. Maeda, and C. F. Semenkovich. 1995. COOH-terminal disruption of lipoprotein lipase in mice is lethal in homozygotes, but heterozygotes have elevated triglycerides and impaired enzyme activity. J. Biol. Chem. 270: 12518–12525.[Abstract/Free Full Text]

  29. Jong, M. C., K. W. van Dijk, V. E. Dahlmans, H. van der Boom, K. Kobayashi, K. Oka, G. Siest, L. Chan, M. H. Hofker, and L. M. Havekes. 1999. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor. Biochem. J. 338: 281–287.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
H. Tao, S. Aakula, N. N. Abumrad, and T. Hajri
Peroxisome proliferator-activated receptor-{gamma} regulates the expression and function of very-low-density lipoprotein receptor
Am J Physiol Endocrinol Metab, January 1, 2010; 298(1): E68 - E79.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Takazawa, T. Yamauchi, A. Tsuchida, M. Takata, Y. Hada, M. Iwabu, M. Okada-Iwabu, K. Ueki, and T. Kadowaki
Peroxisome Proliferator-activated Receptor {gamma} Agonist Rosiglitazone Increases Expression of Very Low Density Lipoprotein Receptor Gene in Adipocytes
J. Biol. Chem., October 30, 2009; 284(44): 30049 - 30057.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
A. A. Pendse, J. M. Arbones-Mainar, L. A. Johnson, M. K. Altenburg, and N. Maeda
Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond
J. Lipid Res., April 1, 2009; 50(Supplement): S178 - S182.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
L. Hu, C. C. van der Hoogt, S. M. S. Espirito Santo, R. Out, K. E. Kypreos, B. J. M. van Vlijmen, T. J. C. Van Berkel, J. A. Romijn, L. M. Havekes, K. W. van Dijk, et al.
The hepatic uptake of VLDL in lrp-ldlr-/-vldlr-/- mice is regulated by LPL activity and involves proteoglycans and SR-BI
J. Lipid Res., July 1, 2008; 49(7): 1553 - 1561.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
C. J. A. Moen, A. P. Tholens, P. J. Voshol, W. de Haan, L. M. Havekes, P. Gargalovic, A. J. Lusis, K. W. van Dyk, R. R. Frants, M. H. Hofker, et al.
The Hyplip2 locus causes hypertriglyceridemia by decreased clearance of triglycerides
J. Lipid Res., October 1, 2007; 48(10): 2182 - 2192.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
A. Fergani, H. Oudart, J.-L. Gonzalez De Aguilar, B. Fricker, F. Rene, J.-F. Hocquette, V. Meininger, L. Dupuis, and J.-P. Loeffler
Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis
J. Lipid Res., July 1, 2007; 48(7): 1571 - 1580.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
H. J. Ting, J. P. Stice, U. Y. Schaff, D. Y. Hui, J. C. Rutledge, A. A. Knowlton, A. G. Passerini, and S. I. Simon
Triglyceride-Rich Lipoproteins Prime Aortic Endothelium for an Enhanced Inflammatory Response to Tumor Necrosis Factor-{alpha}
Circ. Res., February 16, 2007; 100(3): 381 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
T. Claudel, B. Staels, and F. Kuipers
The Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism
Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2020 - 2030.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. Iwasaki, S. Takahashi, M. Takahashi, Y. Zenimaru, T. Kujiraoka, M. Ishihara, M. Nagano, J. Suzuki, I. Miyamori, H. Naiki, et al.
Deficiency of the Very Low-Density Lipoprotein (VLDL) Receptors in Streptozotocin-Induced Diabetic Rats: Insulin Dependency of the VLDL Receptor
Endocrinology, August 1, 2005; 146(8): 3286 - 3294.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Bovenschen, K. Mertens, L. Hu, L. M. Havekes, and B. J. M. van Vlijmen
LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo
Blood, August 1, 2005; 106(3): 906 - 912.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
S. M. S. E. Santo, P. C. N. Rensen, J. R. Goudriaan, A. Bensadoun, N. Bovenschen, P. J. Voshol, L. M. Havekes, and B. J. M. van Vlijmen
Triglyceride-rich lipoprotein metabolism in unique VLDL receptor, LDL receptor, and LRP triple-deficient mice
J. Lipid Res., June 1, 2005; 46(6): 1097 - 1102.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
I. Duivenvoorden, B. Teusink, P. C. Rensen, J. A. Romijn, L. M. Havekes, and P. J. Voshol
Apolipoprotein C3 Deficiency Results in Diet-Induced Obesity and Aggravated Insulin Resistance in Mice
Diabetes, March 1, 2005; 54(3): 664 - 671.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M400009-JLR200v1
45/8/1475    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goudriaan, J. R.
Right arrow Articles by Rensen, P. C. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goudriaan, J. R.
Right arrow Articles by Rensen, P. C. N.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Advertisement
spacer
Advertisement
Advertisement